Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects.
Akpalu DE, Frederick B, Nnane IP, Yao Z, Shen F, Ort T, Fink D, Dogmanits S, Raible D, Sharma A, Xu Z. Akpalu DE, et al. Among authors: frederick b. J Clin Pharmacol. 2019 Jul;59(7):968-978. doi: 10.1002/jcph.1393. Epub 2019 Feb 18. J Clin Pharmacol. 2019. PMID: 30776134 Clinical Trial.
The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis.
Nnane I, Frederick B, Yao Z, Raible D, Shu C, Badorrek P, van den Boer M, Branigan P, Duffy K, Baribaud F, Fink D, Yang TY, Xu Z. Nnane I, et al. Among authors: frederick b. Br J Clin Pharmacol. 2020 Dec;86(12):2507-2518. doi: 10.1111/bcp.14361. Epub 2020 Jun 14. Br J Clin Pharmacol. 2020. PMID: 32415720 Free PMC article. Clinical Trial.
Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, Doyle MK, Petty KJ, Davis HM, Zhou H. Zhuang Y, et al. Among authors: frederick b. Clin Ther. 2012 Jan;34(1):77-90. doi: 10.1016/j.clinthera.2011.11.015. Epub 2011 Dec 14. Clin Ther. 2012. PMID: 22169051 Clinical Trial.
A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects.
Xu C, Han C, Marini J, Ford J, Marciniak S, Lopez M Jr, Frederick B, de Vries D, Bandekar R, Davis HM, Zhou H, Puchalski TA. Xu C, et al. Among authors: frederick b. Clin Pharmacol Drug Dev. 2014 Jul;3(4):328-34. doi: 10.1002/cpdd.86. Epub 2013 Nov 22. Clin Pharmacol Drug Dev. 2014. PMID: 27128840 Clinical Trial.
A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects.
Bouman-Thio E, Franson K, Miller B, Getsy J, Cohen A, Bai SA, Yohrling J, Frederick B, Marciniak S, Jiao Q, Jang H, Davis H, Burggraaf J. Bouman-Thio E, et al. Among authors: frederick b. J Clin Pharmacol. 2008 Oct;48(10):1197-207. doi: 10.1177/0091270008322907. J Clin Pharmacol. 2008. PMID: 18812609 Clinical Trial.
198 results